Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274534 · ClinicalTrials.gov registry record · Phase 3
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT00274534 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 36 participants.
The verdict
NCT00274534, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
Interventions
- DRUG Tiotropium
- DRUG Salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-12 |
| Est. Completion | 2003-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274534
The ClinicalTrials.gov registry entry for NCT00274534 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium is the first listed.
NCT00274534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274534 about?
NCT00274534 is a clinical study titled "A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.". To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
What is the current status of trial NCT00274534?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2000-12. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00274534?
The interventions under investigation include: Tiotropium (DRUG), Salmeterol (DRUG).
Who is sponsoring clinical trial NCT00274534?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.